• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核糖体蛋白在p53调控中的核心作用。

The Central Role of Ribosomal Proteins in p53 Regulation.

作者信息

Lindström Mikael S

机构信息

Department of Medical Biochemistry and Biophysics, Division of Genome Biology, Science for Life Laboratory, Karolinska Institutet, SE-171 21 Stockholm, Sweden.

出版信息

Cancers (Basel). 2025 May 8;17(10):1597. doi: 10.3390/cancers17101597.

DOI:10.3390/cancers17101597
PMID:40427096
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12110047/
Abstract

The tumor suppressor protein p53 prevents the malignant transformation of cells by responding to DNA damage, oncogene activation, and abnormal growth signals including ribosome assembly defects. Under normal conditions, p53 activity is controlled by the regulatory proteins MDM2 and MDM4, which suppress its function through ubiquitin-mediated degradation and transcriptional inhibition. A subset of ribosomal proteins initiates the p53 response to impaired ribosome biogenesis. The ability of some ribosomal proteins to control MDM2 and MDM4 activities, and thereby p53, underscores an intriguing aspect of cell biology: proteins primarily known for their roles in ribosome function can exert extra-ribosomal functions. One notable example is the cellular RNA-protein complex involving RPL5, RPL11, and 5S rRNA (5S RNP) which inhibits MDM2 and stabilizes p53. Another RP, is frequently mutated in cancers with microsatellite instability and its paralog is often amplified. Recent studies have revealed that RPL22 directly modulates the alternative splicing of to promote p53 activation, suggesting that the ribosomal protein-p53 relationship is more complex than previously thought. Cellular responses to ribosome biogenesis inhibition extend beyond general alterations in transcription and translation to actively determine cancer cell fate by selectively engaging tumor-suppressor pathways. RPL22's effect on and other mRNA splicing events is a striking example. A better understanding of the mechanisms involved could guide the development of improved cancer treatments.

摘要

肿瘤抑制蛋白p53通过对DNA损伤、癌基因激活以及包括核糖体组装缺陷在内的异常生长信号作出反应,来防止细胞发生恶性转化。在正常情况下,p53的活性受调控蛋白MDM2和MDM4的控制,它们通过泛素介导的降解和转录抑制来抑制p53的功能。一部分核糖体蛋白启动了p53对核糖体生物发生受损的反应。一些核糖体蛋白控制MDM2和MDM4活性进而控制p53的能力,凸显了细胞生物学中一个有趣的方面:主要因其在核糖体功能中所起作用而为人所知的蛋白质可以发挥核糖体之外的功能。一个显著的例子是涉及RPL5、RPL11和5S rRNA的细胞RNA-蛋白质复合物(5S RNP),它可抑制MDM2并稳定p53。另一种核糖体蛋白在具有微卫星不稳定性的癌症中经常发生突变,其旁系同源物则常常扩增。最近的研究表明,RPL22直接调节……的可变剪接以促进p53激活,这表明核糖体蛋白与p53的关系比之前认为的更为复杂。细胞对核糖体生物发生抑制的反应不仅限于转录和翻译的一般变化,还通过选择性地激活肿瘤抑制途径来积极决定癌细胞的命运。RPL22对……和其他mRNA剪接事件的影响就是一个显著的例子。更好地理解其中涉及的机制可以指导改进癌症治疗方法的开发。 (注:原文中“Another RP, is frequently mutated...”和“RPL22's effect on and other mRNA splicing events...”两处有信息缺失)

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/0563a34ed940/cancers-17-01597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/444d62f6551b/cancers-17-01597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/5477b2cbe316/cancers-17-01597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/0563a34ed940/cancers-17-01597-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/444d62f6551b/cancers-17-01597-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/5477b2cbe316/cancers-17-01597-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b080/12110047/0563a34ed940/cancers-17-01597-g003.jpg

相似文献

1
The Central Role of Ribosomal Proteins in p53 Regulation.核糖体蛋白在p53调控中的核心作用。
Cancers (Basel). 2025 May 8;17(10):1597. doi: 10.3390/cancers17101597.
2
Cancer-mutated ribosome protein L22 (RPL22/eL22) suppresses cancer cell survival by blocking p53-MDM2 circuit.癌症突变的核糖体蛋白L22(RPL22/eL22)通过阻断p53-MDM2回路来抑制癌细胞存活。
Oncotarget. 2017 Oct 6;8(53):90651-90661. doi: 10.18632/oncotarget.21544. eCollection 2017 Oct 31.
3
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4.RPL22 是 MSI-high 癌症中的肿瘤抑制因子,也是 MDM4 的剪接调节因子。
Cell Rep. 2024 Aug 27;43(8):114622. doi: 10.1016/j.celrep.2024.114622. Epub 2024 Aug 14.
4
The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress.核糖体蛋白 L22 结合 MDM4 前体 mRNA 并促进外显子跳跃,从而在核仁应激时激活 p53。
Cell Rep. 2024 Aug 27;43(8):114610. doi: 10.1016/j.celrep.2024.114610. Epub 2024 Aug 7.
5
The pre-existing population of 5S rRNA effects p53 stabilization during ribosome biogenesis inhibition.5S核糖体RNA的既有群体在核糖体生物合成抑制过程中影响p53蛋白的稳定性。
Oncotarget. 2017 Jan 17;8(3):4257-4267. doi: 10.18632/oncotarget.13833.
6
The 5S RNP couples p53 homeostasis to ribosome biogenesis and nucleolar stress.5S RNP 将 p53 内稳态与核糖体生物发生和核仁应激联系起来。
Cell Rep. 2013 Oct 17;5(1):237-47. doi: 10.1016/j.celrep.2013.08.049. Epub 2013 Oct 10.
7
Ribosomal RNA transcription governs splicing through ribosomal protein RPL22.核糖体RNA转录通过核糖体蛋白RPL22控制剪接。
bioRxiv. 2024 Aug 16:2024.08.15.608201. doi: 10.1101/2024.08.15.608201.
8
Perturbation of RNA Polymerase I transcription machinery by ablation of HEATR1 triggers the RPL5/RPL11-MDM2-p53 ribosome biogenesis stress checkpoint pathway in human cells.HEATR1 缺失导致 RNA 聚合酶 I 转录机制受到干扰,从而在人细胞中引发 RPL5/RPL11-MDM2-p53 核糖体生物发生应激检查点途径。
Cell Cycle. 2018;17(1):92-101. doi: 10.1080/15384101.2017.1403685. Epub 2017 Dec 10.
9
Oncogenic MYC Induces the Impaired Ribosome Biogenesis Checkpoint and Stabilizes p53 Independent of Increased Ribosome Content.致癌性 MYC 诱导受损核糖体生物发生检查点,并稳定 p53 独立于核糖体含量增加。
Cancer Res. 2019 Sep 1;79(17):4348-4359. doi: 10.1158/0008-5472.CAN-18-2718. Epub 2019 Jul 10.
10
5S ribosomal RNA is an essential component of a nascent ribosomal precursor complex that regulates the Hdm2-p53 checkpoint.5S 核糖体 RNA 是新生核糖体前体复合物的必需成分,该复合物调节 Hdm2-p53 检查点。
Cell Rep. 2013 Jul 11;4(1):87-98. doi: 10.1016/j.celrep.2013.05.045. Epub 2013 Jul 3.

本文引用的文献

1
Ribosomal protein paralogues in ribosome specialization.核糖体特化中的核糖体蛋白旁系同源物。
Philos Trans R Soc Lond B Biol Sci. 2025 Mar 6;380(1921):20230387. doi: 10.1098/rstb.2023.0387.
2
Ribosome specialization by cancer-associated ribosomal protein mutations: progress made and open questions.癌症相关核糖体蛋白突变导致的核糖体特化:取得的进展与待解决的问题
Philos Trans R Soc Lond B Biol Sci. 2025 Mar 6;380(1921):20230380. doi: 10.1098/rstb.2023.0380.
3
MDM4 exon skipping upon dysfunctional ribosome assembly.核糖体组装功能失调时MDM4外显子跳跃。
Trends Cell Biol. 2024 Nov 7. doi: 10.1016/j.tcb.2024.10.006.
4
SURF2 is a MDM2 antagonist in triggering the nucleolar stress response.SURF2 是一种 MDM2 拮抗剂,可触发核仁应激反应。
Nat Commun. 2024 Sep 27;15(1):8404. doi: 10.1038/s41467-024-52659-x.
5
RPL22L1 is a novel biomarker for prognosis and immune infiltration in lung adenocarcinoma, promoting the growth and metastasis of LUAD cells by inhibiting the MDM2/P53 signaling pathway.RPL22L1 是肺腺癌预后和免疫浸润的新型生物标志物,通过抑制 MDM2/P53 信号通路促进 LUAD 细胞的生长和转移。
Aging (Albany NY). 2024 Aug 28;16(17):12392-12413. doi: 10.18632/aging.206096.
6
Epstein-Barr virus noncoding RNA EBER1 promotes the expression of a ribosomal protein paralog to boost oxidative phosphorylation.爱泼斯坦-巴尔病毒非编码 RNA EBER1 促进核糖体蛋白旁系同源物的表达,从而促进氧化磷酸化。
J Med Virol. 2024 Aug;96(8):e29869. doi: 10.1002/jmv.29869.
7
RPL22 is a tumor suppressor in MSI-high cancers and a splicing regulator of MDM4.RPL22 是 MSI-high 癌症中的肿瘤抑制因子,也是 MDM4 的剪接调节因子。
Cell Rep. 2024 Aug 27;43(8):114622. doi: 10.1016/j.celrep.2024.114622. Epub 2024 Aug 14.
8
The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress.核糖体蛋白 L22 结合 MDM4 前体 mRNA 并促进外显子跳跃,从而在核仁应激时激活 p53。
Cell Rep. 2024 Aug 27;43(8):114610. doi: 10.1016/j.celrep.2024.114610. Epub 2024 Aug 7.
9
Decoding ribosome complexity: role of ribosomal proteins in cancer and disease.解码核糖体复杂性:核糖体蛋白在癌症和疾病中的作用。
NAR Cancer. 2024 Jul 23;6(3):zcae032. doi: 10.1093/narcan/zcae032. eCollection 2024 Sep.
10
Ribosome specialization in cancer: a spotlight on ribosomal proteins.癌症中的核糖体特化:聚焦核糖体蛋白
NAR Cancer. 2024 Jul 9;6(3):zcae029. doi: 10.1093/narcan/zcae029. eCollection 2024 Sep.